再生不良性貧血治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Aplastic Anemia - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0597
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:107
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Aplastic Anemia – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia – Pipeline Review, H2 2019, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aplastic Anemia – Overview
Aplastic Anemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aplastic Anemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aplastic Anemia – Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Advanced Medical Projects
Amgen Inc
ASC Therapeutics Inc
BioLineRx Ltd
Cell Source Inc
Cellenkos Inc
Elixirgen Therapeutics LLC
F. Hoffmann-La Roche Ltd
Gamida Cell Ltd
HemoGenyx LLC
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Regen BioPharma Inc
Aplastic Anemia – Drug Profiles
Aplastic Anemia – Dormant Projects
Aplastic Anemia – Discontinued Products
Aplastic Anemia – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Aplastic Anemia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H2 2019
Aplastic Anemia - Pipeline by Advanced Medical Projects, H2 2019
Aplastic Anemia - Pipeline by Amgen Inc, H2 2019
Aplastic Anemia - Pipeline by ASC Therapeutics Inc, H2 2019
Aplastic Anemia - Pipeline by BioLineRx Ltd, H2 2019
Aplastic Anemia - Pipeline by Cell Source Inc, H2 2019
Aplastic Anemia - Pipeline by Cellenkos Inc, H2 2019
Aplastic Anemia - Pipeline by Elixirgen Therapeutics LLC, H2 2019
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Aplastic Anemia - Pipeline by Gamida Cell Ltd, H2 2019
Aplastic Anemia - Pipeline by HemoGenyx LLC, H2 2019
Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Aplastic Anemia - Pipeline by Novartis AG, H2 2019
Aplastic Anemia - Pipeline by Regen BioPharma Inc, H2 2019
Aplastic Anemia - Dormant Projects, H2 2019
Aplastic Anemia - Discontinued Products, H2 2019

【掲載企業】

Acceleron Pharma Inc
Advanced Medical Projects
Amgen Inc
ASC Therapeutics Inc
BioLineRx Ltd
Cell Source Inc
Cellenkos Inc
Elixirgen Therapeutics LLC
F. Hoffmann-La Roche Ltd
Gamida Cell Ltd
HemoGenyx LLC
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Regen BioPharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[再生不良性貧血治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆